INVO Fertility, Inc.
Close on Oct 19, 2026
- Market cap
- $1.56M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 16, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 17, 2026 | Before market open | $2.18M | $0.35 | – |
| Q1 FY2026 Ended Mar 31, 2026 | Jun 2, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 17, 2025 | Before market open | $1.76M | $-0.77 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 15, 2025 | During market hours | $1.86M | $-13.30 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Apr 30, 2025 | Before market open | $1.69M | $-9.04 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 14, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | Apr 16, 2024 | After market close | $1.38M | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 13, 2023 | After market close | $974.89K | – | – |
| Q2 FY2023 Ended Jun 30, 2023 | Aug 14, 2023 | After market close | – | – | – |
| Q1 FY2023 Ended Mar 31, 2023 | May 15, 2023 | After market close | – | – | – |
| Q4 FY2022 Ended Dec 31, 2022 | Mar 30, 2023 | After market close | – | – | – |
Press releases
Announcements INVO Fertility filed with the SEC
EX-99.1 to Form 8-K
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Fertility Reports Second Quarter 2026 Results Highlighting Revenue Growth and Clinic Platform Profitability
Results of operations · EX-99.1 to Form 8-K
Fertility Reports First Quarter 2026 Results
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Fertility Announces Fiscal Year 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Fertility Receives Nasdaq Notification Regarding Late Filing of Annual Report on Form 10-K
Listing notice · Regulation FD disclosure · EX-99.1 to Form 8-K
Fertility Announces a 1:5 Reverse Stock Split Effective Pre-Market Opening on March 27, 2026
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Fertility Closes Acquisition of Indiana-Based Fertility Clinic “Family Beginnings”
Material agreement · Acquisition or disposition completed · Unregistered share sale · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Fertility Enters into $7.5 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rules
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Fertility Aligns Executive Leadership Structure to Support Growth Strategy
Executive or director change · Other events · EX-99.1 to Form 8-K
Fertility Signs Definitive Purchase Agreement to Acquire Indiana-Based Fertility Clinic “Family Beginnings”
Material agreement · Other events · EX-99.1 to Form 8-K
Fertility Announces Pricing of $4.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Fertility Announces a 1:8 Reverse Stock Split Effective Pre-Market Opening on November 28, 2025
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Fertility Announces Third Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Fertility Announces Second Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Fertility Announces a 1:3 Reverse Stock Split Effective Pre-Market Opening on July 21, 2025
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Fertility Announces First Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Fertility Announces 2024 Financial Results with 116% Annual Revenue Growth and Further Improvements in Adjusted EBITDA
Results of operations · EX-99.1 to Form 8-K
Announces a 1:12 Reverse Stock Split Effective Pre-Market Opening on March 18, 2025
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Material agreement · Listing notice · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
Bioscience and NAYA Biosciences Close Merger, Combined Company to Operate as NAYA Biosciences (NASDAQ: NAYA)
Material agreement · Acquisition or disposition completed · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Reports Record Second Quarter 2024 Financial Results with 481% Revenue Growth and a $1.1 Million Improvement to Adjusted EBITDA
Results of operations · EX-99.1 to Form 8-K
Reports Record First Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Reports Fourth Quarter and Full Year 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Bioscience Regains Compliance with Nasdaq Minimum Stockholders’ Equity Requirement
Other events · EX-99.1 to Form 8-K
Reports Record Third Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Bioscience Announces Commencement of Waiver Solicitation From Holders of the Company’s Common Stock Purchase Warrants
Other events · EX-99.1 to Form 8-K
of Waiver Solicitation Dated November 9, 2023
Other events · EX-99.2 to Form 8-K
Bioscience and NAYA Biosciences Announce Definitive Merger Agreement To Establish Expanded Publicly Traded Life Science Company
Material agreement · Other events · EX-99.1 to Form 8-K
BIOSCIENCE ANNOUNCES ADJOURNMENT OF SPECIAL MEETING OF SHAREHOLDERS
Other events · EX-99.1 to Form 8-K
Reports Second Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Closes Acquisition of Wisconsin Fertility Institute
Material agreement · Acquisition or disposition completed · Other events · EX-99.1 to Form 8-K
PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS
Material agreement · Acquisition or disposition completed · Other events · EX-99.4 to Form 8-K
Bioscience Announces Pricing of $4.5 Million Public Offering
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Bioscience Announces Closing of $4.5 Million Public Offering
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.2 to Form 8-K
Announces a 1:20 Reverse Stock Split Effective Pre-Market Opening on July 28, 2023
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
INVO Reports First Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Reports Fourth Quarter and Full Year 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K